Skip to main content
Premium Trial:

Request an Annual Quote

David U'Prichard

Premium
Drug developer CoGenesys said that David U’Prichard has been appointed to the company’s board of directors.
 
U’Prichard currently sits on the boards of Invitrogen and SR Pharma, the parent firm of Atugen.

 

 
Note to Readers: This is the last issue of RNAi News to publish in 2006. The next issue of the newsletter will appear on Thursday, Jan. 4.
The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.